The biotech industry is severely lagging the market this year, at least according to the SPDR S&P Biotech ETF, an industry benchmark that is down about 14% so far in 2023. However, that doesn't mean you should avoid biotech stocks altogether. Even as the sector may struggle near term, some companies still have the tools to perform well in the long run.

Let's look at two biotech stocks worth buying right now: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Although they've moved in opposite directions this year, both are worth serious consideration.

Continue reading

Source Fool.com